Alvotech Raises Further Funds After FDA Green Light
Biosimilars Developer Accepts $166m Offer For 10.1m Shares Following US Approval
Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.
